Brief: Merck And Eisai Announce WELIREG Plus LENVIMA Met Primary Endpoint Of Progression-Free Survival In Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
28/10/2025 10:31
Oct 28 (Reuters) - Merck & Co Inc MRK.N: MERCK AND EISAI ANNOUNCE WELIREG® (BELZUTIFAN) PLUS LENVIMA® (LENVATINIB) MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) IN CERTAIN PREVIOUSLY TREATED PATIENTS WITH ADVANCED RENAL CELL CARCINOMA MERCK & CO INC - WELIREG PLUS LENVIMA COMBINATION SHOWS SIGNIFICANT ORR IMPROVEMENT MERCK: SAFETY PROFILES OF WELIREG & LENVIMA IN TRIAL CONSISTENT WITH THOSE OBSERVED IN PREVIOUSLY REPORTED STUDIES FOR INDIVIDUAL THERAPIES Source text: ID:nBwbHWMBXa Further company coverage: MRK.N
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China